Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7376
Source ID: NCT06059287
Associated Drug: Henagliflozin
Title: The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics
Acronym:
Status: NOT_YET_RECRUITING
Study Results: NO
Results:
Conditions: Obesity|Type 2 Diabetes|Sodium-glucose Co-transporter-2 Inhibitor|Myocardial Fibrosis|Magnetic Resonance Imaging
Interventions: DRUG: Henagliflozin|DRUG: Metformin
Outcome Measures: Primary: Extra-cellular volume fraction, To compare the effects of henagliflozin and metformin on extra-cellular volume fraction, baseline and week 24 | Secondary: Mean Change in HbA1c Levels, To compare the effects of henagliflozin and metformin on HbA1c Levels, baseline and week 24|Mean change in body mass index, To compare the effects of henagliflozin and metformin on body mass index, baseline and week 24|Mean change in blood pressure, To compare the effects of henagliflozin and metformin on blood pressure, baseline and week 24|Mean change in level of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), To compare the effects of henagliflozin and metformin on level of Homeostatic Model Assessment of Insulin Resistance, baseline and week 24|Native T2 mapping, To compare the effects of henagliflozin and metformin on native T2 mapping, baseline and week 24
Sponsor/Collaborators: Sponsor: RenJi Hospital
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 64
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2023-10-01
Completion Date: 2025-12-31
Results First Posted:
Last Update Posted: 2023-09-28
Locations:
URL: https://clinicaltrials.gov/show/NCT06059287

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D445 Dapagliflozin small molecule DB06292 Details
D089 Metformin small molecule DB00331 Details